Blinklab Limited ( (AU:BB1) ) has provided an announcement.
BlinkLab Limited has initiated a significant FDA registrational study aimed at improving diagnostics and care for autism, following positive feedback from a pre-submission meeting with the FDA. The study, which includes a pilot phase and a larger main study, is designed to ensure high data quality and diagnostic accuracy, potentially leading to regulatory approval for BlinkLab Dx 1, their diagnostic tool for autism. Their partnership with Monash University on the MAGNET study further underscores their commitment to advancing neurodevelopmental research.
More about Blinklab Limited
BlinkLab Limited is an innovative digital healthcare company that leverages smartphones, computer vision, Artificial Intelligence, and Machine Learning to diagnose neurodevelopmental conditions such as autism and ADHD.
YTD Price Performance: 5.36%
Average Trading Volume: 166,179
Technical Sentiment Consensus Rating: Strong Sell
Find detailed analytics on BB1 stock on TipRanks’ Stock Analysis page.